Pirmitegravir
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2023 (NCT05869643)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Q7ZJM1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2c(c(C)c(C)n2Cc2cnn(C)c2)c(-c2ccc(Cl)cc2)c1[C@H](OC(C)(C)C)C(=O)O- Mol. weight
- 495.02 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095077 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05869643 | Phase 2 | May 23, 2023 | Dong-A Pharmaceutical |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dong-A Pharmaceutical | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1